ReviewDiabetologia2016
Blood-based signatures in type 1 diabetes.
Review in Diabetologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Current Status of Metabolic/Bariatric Surgery in Type 1 Diabetes Mellitus: an Updated Systematic Review and Meta-analysis.Obesity surgery · 2022Pooled it
- Probiotic normalization of systemic inflammation in siblings of type 1 diabetes patients: an open-label pilot study.Scientific reports · 2022Trial
- Article
- Immunomodulatory effects of primed amniotic fluid-derived mesenchymal stem/stromal cells with IFN-γ from unexplained recurrent miscarriage sources.Scientific reports · 2026Article
- Children With Celiac Disease Have a Higher Degree of Activated or Exhausted CD4Scandinavian journal of immunology · 2025Article
- Molecular inflammatory expression profiles associated with the frequency of pain in individuals with sickle cell disease.Blood advances · 2025Article
- Monocytes in type 1 diabetes families exhibit high cytolytic activity and subset abundances that correlate with clinical progression.Science advances · 2024Article
- Systematic immune cell dysregulation and molecular subtypes revealed by single-cell RNA-seq of subjects with type 1 diabetes.Genome medicine · 2024Article
- Supervised Parametric Learning in the Identification of Composite Biomarker Signatures of Type 1 Diabetes in Integrated Parallel Multi-Omics Datasets.Biomedicines · 2024Article
- RNA Sequencing Analysis of CD4Critical care explorations · 2023Article
- Article
- Modeling human T1D-associated autoimmune processes.Molecular metabolism · 2022Review
- Environmental Triggering of Type 1 Diabetes Autoimmunity.Frontiers in endocrinology · 2022Review
- Type 1 diabetes mellitus: much progress, many opportunities.The Journal of clinical investigation · 2021Review
- Transcriptional networks in at-risk individuals identify signatures of type 1 diabetes progression.Science translational medicine · 2021Article
- Lactobacillus plantarum 299v probiotic supplementation in men with stable coronary artery disease suppresses systemic inflammation.Scientific reports · 2021Article
- Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs.BioMed research international · 2021Article
- High Glucose Causes Distinct Expression Patterns of Primary Human Skin Cells by RNA Sequencing.Frontiers in endocrinology · 2021Article
- Phytochemicals as Anti-Inflammatory Agents in Animal Models of Prevalent Inflammatory Diseases.Molecules (Basel, Switzerland) · 2020Review
- Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.Diabetes care · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Type 1 diabetes mellitus is one of the most common chronic diseases in childhood. It develops through autoimmune destruction of the pancreatic beta cells and results in lifelong dependence on exogenous insulin. The pathogenesis of type 1 diabetes involves a complex interplay of genetic and environmental factors and has historically been attributed to aberrant adaptive immunity; however, there is increasing evidence for a role of innate inflammation. Over the past decade new methodologies for the analysis of nucleic acid and protein signals have been applied to type 1 diabetes. These studies are providing a new understanding of type 1 diabetes pathogenesis and have the potential to inform the development of new biomarkers for predicting diabetes onset and monitoring therapeutic interventions. In this review we will focus on blood-based signatures in type 1 diabetes, with special attention to both direct transcriptomic analyses of whole blood and immunocyte subsets, as well as plasma/serum-induced transcriptional signatures. Attention will also be given to proteomics, microRNA assays and markers of beta cell death. We will also discuss the results of blood-based profiling in type 1 diabetes within the context of the genetic and environmental factors implicated in the natural history of autoimmune diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.